Aptinyx discovers and develops
innovative therapies for
challenging disorders of the brain and
nervous system.

nerve 650

Aptinyx's proprietary compounds modulate
the NMDA receptor,
a critical regulator
involved in nerve cell
communication.

Aptinyx seeks to leverage its experience and
track record of success to rapidly advance promising therapies in development for patients in need.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative therapies for challenging neurologic disorders. Aptinyx has a proven platform for discovering compounds that work through a novel mechanism: modulation of NMDA receptors to enhance communication between neural cells.

Learn more about Aptinyx »

Latest News

April 18, 2019
Robust Analgesic Activity of Aptinyx’s NYX-2925 in Advanced DPN Patients Revealed Through Further Analysis of Data from Phase 2 Study

April 4, 2019
Aptinyx to Present at 18th Annual Needham Healthcare Conference

April 3, 2019
Data in Parkinson’s Disease Model in Non-human Primates Demonstrate Reversal of Cognitive Deficits with Novel NMDA Receptor Modulator, NYX-458

March 28, 2019
Aptinyx to Present Detailed Results from Phase 2 Painful DPN Study of NYX-2925 at American Pain Society Scientific Meeting

March 22, 2019
Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Diseases

See all press and news »